Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 Oral Treatment in Adults With Essential Tremor

NCT03688685 is registered in ClinicalTrials.gov with Cadent Therapeutics as lead sponsor.

NCT NCT03688685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03688685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 Oral Treatment in Adults With Essential Tremor
Lead sponsor
Cadent Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
January 23, 2019
Completion date
September 24, 2019
Enrollment
25 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

essential tremor